The Canadian Cancer Society forecasts that roughly 45% of Canadians will face a cancer diagnosis in their lifetime.
And those with cancer must navigate the complexities of treatment, an added stress.
In response to this, Desjardins Insurance this month launched a Cancer Care Focus initiative, designed to give plan members access to tools and resources that make care more personalized and effective.
“Cancer affects nearly one in two Canadians, and early detection is critical,” explains Dr. Neda Nasseri, Product Director of Drug Insurance at Desjardins Insurance.
The Quebec-based financial firm is working with Calgary-born OncoHelix, Ottawa’s Constant Health, and Sword Health out of New York City to deliver the offering.
Specifically, Desjardins is partnering with OncoHelix to offer coverage for advanced biomarker testing.
These diagnostics help identify tumour-driving mutations and match patients with targeted therapies or clinical trials, enabling earlier and more personalized treatment decisions.
“Our goal is to meet plan members where they are, physically, emotionally and financially,” Nasseri stated.
OncoHelix was founded in Alberta in 2019 and has since then become Canada’s premier precision diagnostics laboratory offering molecular and immune profile testing that meets the highest clinical standards.
“The partnerships with OncoHelix, Constant Health, and Sword Health will allow our plan members to receive high-quality care from home, while removing barriers and improving the recovery experience,” Nasseri said.
Founded in Lévis in 1900, Desjardins Group is the largest cooperative financial group in North America and the fifth largest in the world.
Leave a Reply